Target intelligence / Profile preview

ATP-sensitive potassium channel (KATP channel), pancreatic beta cell (KATP channel)

Target
KATP channel
Molecular classification
Ion channel
01

Overview

The ATP-sensitive potassium channel (KATP channel) in pancreatic beta cells is an octameric complex of four Kir6.2 pore-forming subunits (encoded by KCNJ11) and four sulfonylurea receptor 1 (SUR1) regulatory subunits (encoded by ABCC8), functioning as a metabolic sensor that links glucose levels to insulin secretion. Under low glucose, high ADP/ATP ratios keep channels open, maintaining hyperpolarized membrane potential; elevated glucose boosts ATP, closing channels, depolarizing the cell, opening voltage-gated calcium channels, and triggering calcium-dependent insulin exocytosis. Mutations in KCNJ11 or ABCC8 cause diseases like neonatal diabetes (reduced function) or congenital hyperinsulinism (gain-of-function), highlighting its role in glucose homeostasis. Therapeutically, sulfonylureas like glibenclamide bind SUR1 to inhibit channels and boost insulin for type 2 diabetes treatment, while diazoxide opens channels to suppress insulin in hyperinsulinism. Structural studies reveal nucleotide binding at Kir6.2 interfaces and SUR1 conformational changes coupling metabolism to gating, with challenges including hypoglycemia risk and tissue-specific isoforms.

Other names
K-ATP channelbeta-cell inward rectifier subunit (BIR)inward rectifier K(+) channel Kir6.2 (KIR6.2)ATP-sensitive inward rectifier potassium channel 11
02

Mechanism of action

Closure by sulfonylureas to depolarize beta cells and promote insulin release; opening by diazoxide to hyperpolarize and inhibit insulin secretion

03

Biological functions

Glucose-stimulated insulin secretionsignal transductionmetabolic sensing
04

Disease associations

Diabetes mellituscongenital hyperinsulinismneonatal diabetes
05

Safety considerations

Hypoglycemia from sulfonylurea overstimulationrisk of cardiovascular effects from off-target KATP channel modulation in heart or vasculature
06

Interacting drugs

Sulfonylureas (e.g., glibenclamide)

3 more in the full profile.

07

Biomarkers

KCNJ11 and ABCC8 gene mutations for patient selection in neonatal diabetes or hyperinsulinism

Beyond the preview

Go deeper on ATP-sensitive potassium channel (KATP channel), pancreatic beta cell (KATP channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel (KATP channel), pancreatic beta cell (KATP channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call